← Back to headlines
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny
4 Mar, 07:30 — 4 Mar, 07:30
Sources
Showing 1 of 1 sources
Related Stories
Irish Health Agency Fined €645,000 for Storing Records in Derelict Sites
2h ago
New Urine Test Detects Over 90 Percent of Bladder Cancer Cases
2h ago
Swimmer Hospitalized Following Suspected Shark Attack in Massachusetts
6h ago
Wellington Clinics Suspends Kidney Transplants Amid Organ Harvesting Probe
11h ago